1. Fig. 4. Activation of type‐1‐dependent antitumor cellular immunity by repeated DC1/T_h1 tumor‐vaccine cell therapy in tumor‐bearing mice. (A) A20‐OVA tumor‐bearing mice were treated with none (solid circles), DC1, T_h1 and MMC‐A20‐OVA (DC1/T_h1 tumor‐vaccine cell therapy) once (open circles) or 3 times (open triangles). The number in parentheses indicates the percentage of cured mice among all tumor‐bearing mice. The data represents mean ± SE of five mice. (B) Serum samples were obtained from tumor‐bearing mice treated with DC1/T_h1 tumor‐vaccine cell therapy 24 h after final vaccine therapy. As a control, serum samples were obtained from untreated tumor‐bearing mice. Serum IFN‐γ levels were measured by ELISA. The data represents mean ± SE of three mice. (C) Increase of IFN‐γ‐producing T_h1 and T_c1 cells by DC1/T_h1 tumor‐vaccine therapy. Spleen cells were prepared from control mice or mice treated with DC1/T_h1 vaccine therapy three times. The percentages of IL‐4‐ and IFN‐γ‐producing cells were measured by intracellular staining. (D) Spleen cells obtained from untreated (triangles) or DC1/T_h1‐treated tumor‐bearing mice (circles) were re‐stimulated with OVA for 4 days. After culture, the cytotoxicity of CD8⁺ T cells against A20‐OVA (solid symbols) or P815 tumor cells (open symbols) was measured by 4‐h ⁵¹Cr‐release assay. The data represents mean ± SE of three mice.
A novel tumor‐vaccine cell therapy using bone marrow‐derived dendritic cell type 1 and antigen‐specific Th1 cells
Int Immunol. 2003;15(7): doi: /intimm/dxg081
Int Immunol | 1